BPC-157 TB-500 FAQ: The Wolverine Blend, Answered From the Record

Definitions and overview

BPC-157 TB-500 FAQ entries are grouped below, from definitions through mechanisms, dosage, safety, and regulatory status. Each answer leads with the answer and cites the study behind any number.

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein, and TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) matching residues 17-23 of Thymosin Beta-4 ^[3][5]. The Wolverine blend pairs the two as a research-community tissue-repair stack; it is not a single chemical entity and not an approved product.

What is the Wolverine peptide blend?

Wolverine is a research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair stack. It is not a single chemical entity, has no single molecular weight or CAS number, and is not an approved product anywhere ^[6].

What is the BPC-157 and TB-500 blend used for in research?

In preclinical work its two components occupy complementary nodes of a tissue-repair network: BPC-157 for cytoprotection, angiogenesis, and tendon/ligament repair in rodent models ^[1][2], and TB-500 / Thymosin Beta-4 for cell migration, re-epithelialization, and wound healing in animal and biochemical models ^[3][4]. The assembled blend itself has not been tested in a controlled study ^[6].

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric-juice protein, acting through VEGFR2-driven angiogenesis and cytoprotection ^[1][2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ) of Thymosin Beta-4, acting through G-actin sequestration that regulates cell migration ^[3][5]. They differ in size, origin, and primary mechanism, which is why the literature pairs them as complementary repair signals ^[4].

The combination claim

These questions go to the heart of the "Wolverine" pairing: whether combining the two peptides is supported by evidence or by mechanism alone.

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The published rationale rests on complementary mechanisms: BPC-157 contributes a local cytoprotective, pro-angiogenic signal (VEGFR2-Akt-eNOS) ^[2], while TB-500 / Thymosin Beta-4 contributes an intracellular actin-sequestration signal (1:1 G-actin binding via LKKTETQ) that regulates cell migration ^[3]. The literature describes these as complementary but largely non-overlapping pathways; the synergy framing is an extrapolation, not a demonstrated combined effect ^[4][6].

Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No published study defines a synergy ratio, dose, or endpoint for the two peptides given together. A 2025 systematic review of BPC-157 in orthopaedic sports medicine (36 studies, only one human, "no clinical safety data") reports no TB-500 or combination data at all ^[6]. In the reviewed record, synergy is inferred from each peptide's separate mechanism rather than measured in a controlled study.

Is the 'Wolverine' synergy claim actually proven?

Not in the reviewed literature. The Wolverine synergy claim is a mechanistic extrapolation from two largely non-overlapping pathways, not a finding from a controlled combination study ^[4][6]. The most defensible recent reviews bound each component honestly and confirm that no combination data exist ^[6][8].

How does BPC-157 work compared to TB-500?

BPC-157 acts through a cytoprotective/angiogenic route, up-regulating VEGFR2 with downstream Akt-eNOS signaling and modulating the nitric-oxide system ^[2], while TB-500 acts through actin sequestration that regulates cell migration ^[3]. The literature frames them as complementary but largely non-overlapping mechanisms, which is the stated rationale for pairing them in the blend ^[4].

Evidence and clinical data

How strong is the underlying evidence, and what do recent reviews conclude?

Are there human clinical trials on the BPC-157 + TB-500 combination?

The literature records no controlled clinical trials of the combination for any indication. Human data exist only for the individual constituents and remain thin: BPC-157 has three small pilot studies, and the human "TB-500" data are actually for full-length Thymosin Beta-4, not the heptapeptide ^[4][6]. The blend's human efficacy and combination safety are unproven ^[6].

What is the latest research on BPC-157 and TB-500?

The freshest defensible literature is review-level: a 2025 systematic review and a 2025 narrative review of BPC-157, both concluding the evidence is low-tier and that BPC-157 should be treated as investigational ^[6][8], and a 2026 Sports Medicine narrative review listing both BPC-157 and TB-500 that notes animal-model promise but scarce human safety data and no regulatory approval ^[7].

What do doctors and reviews say about the BPC-157 + TB-500 blend?

Recent peer-reviewed reviews are cautious: they describe preclinical promise for the constituents but stress that human data are extremely limited, that BPC-157 should be considered investigational given regulatory controversy and non-regulated availability, and that rigorous human safety data for unapproved musculoskeletal peptides are scarce, with potential for serious harm ^[6][7][8].

Does the BPC-157 TB-500 blend help tendon and ligament injuries?

The tendon/ligament evidence is preclinical and single-compound. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures ^[1], and Thymosin Beta-4 enhanced healing of rat medial collateral ligament injury ^[4]. No controlled study has tested the combined blend in tendon or ligament injury ^[6].

Does BPC-157 and TB-500 help muscle tears and recovery?

Muscle-repair signals in the record are preclinical and single-compound: BPC-157 has been studied in muscle-crush and myotendinous-junction injury in rats, and muscle-injury-induced Thymosin Beta-4 acts as a chemoattractant for myoblasts ^[4]. A notable counter-result is that in mdx mice chronic Thymosin Beta-4 increased regenerating fibers but did not improve strength or cardiac function ^[4]. No combination muscle-recovery trial exists ^[6].

Mechanism

How each constituent works, and how they promote angiogenesis.

How does TB-500 work (actin / Thymosin Beta-4)?

TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization. X-ray crystallography of a gelsolin-domain-Thymosin Beta-4 hybrid bound to actin established this 1:1 dual-end-capping mechanism ^[3]. The literature notes that most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4, not the 7-mer ^[4][5].

Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

Both promote angiogenesis by distinct routes in preclinical models. BPC-157 up-regulates VEGFR2 and promotes its internalization with downstream VEGFR2-Akt-eNOS signaling, increasing vessel density and blood-flow recovery in ischemic muscle ^[2]. Thymosin Beta-4 promotes endothelial migration and angiogenesis, including in aged animals with otherwise poor wound healing ^[4].

Dosage, half-life, and handling

Research-context dosing questions. None of these answers is a human-use instruction.

How do you cycle BPC-157 and TB-500?

No validated human cycling protocol appears in the literature. Community "loading then maintenance" blend schedules have no controlled-trial basis, and a rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic (18 mg/kg gave no benefit), which undercuts "more is better" loading rationales ^[4]. The underlying animal studies use widely differing schedules by species and route.

What is the half-life of BPC-157 and TB-500?

No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog PK study. Human IV full-length Thymosin Beta-4 showed dose-proportional PK, but no specific half-life is established for the TB-500 heptapeptide ^[4].

How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. Commercial vials are commonly labeled with a combined per-vial mass (e.g. 10 mg + 10 mg), but product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. No human-use reconstitution instructions apply to a research chemical.

How often should you inject BPC-157 and TB-500?

The literature records no validated human injection frequency for the blend. The underlying animal studies use widely differing schedules — for example Thymosin Beta-4 at 150 μg twice weekly for six months in one mouse study ^[4] — and community frequency protocols have no controlled-trial basis. Findings should be described as "studied at X in [species]," not framed as human schedules.

Safety and the tumor-signal concern

The honest safety reading, including the recognized — but not demonstrated — tumor signal.

What are the side effects of BPC-157 and TB-500?

The assembled blend has no controlled human safety data. Component human data are limited: a Phase 1 study of full-length Thymosin Beta-4 was well tolerated, but a 2026 review cautions that rigorous human safety data for unapproved musculoskeletal peptides are scarce, with potential for serious harm ^[4][7]. The principal theoretical concern raised in the literature is the pro-angiogenic, pro-migratory tumor signal associated with Thymosin Beta-4 ^[4].

Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression, a concern that compounds when two pro-repair peptides are combined ^[4]. The literature treats this as a recognized safety signal, not a demonstrated effect of the blend, and no carcinogenicity data exist for the combination ^[6].

Regulatory and access

Where the blend's components sit under FDA and WADA rules. General information, not legal advice. See the Wolverine legal status and FDA 503A category page for the full record.

Is Wolverine legal?

Neither constituent is an FDA-approved drug, and the blend has no approved therapeutic indication. As of the most recent confirmable FDA action, both BPC-157 and the TB-500 (LKKTETQ) fragment are 503A Category 2 bulk substances flagged for significant safety risks, which restricts their use in pharmacy compounding ^[9][10]. Both are also prohibited in sport under the World Anti-Doping Code. This is general information, not legal advice.

Can you get BPC-157 from a compounding pharmacy?

BPC-157's compounding access is currently restricted. Effective with the FDA's September 29, 2023 list update, BPC-157 is a 503A Category 2 bulk substance, which is not covered by the FDA's enforcement-discretion policy for compounding ^[9]. It is on the July 23-24, 2026 PCAC agenda as a candidate for the 503A Bulks List, but that is a scheduled review under active evaluation, not a decision or a change in current status ^[11].

What is the FDA 503A status of Wolverine?

Both of Wolverine's components are 503A Category 2: effective with the FDA's September 29, 2023 update, BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" were placed in Category 2 as bulk substances that may present significant safety risks, restricting compounding access ^[9]. Both are on the July 23-24, 2026 PCAC agenda as candidates for the bulks list — a scheduled review, not a listing decision ^[11].

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use, and the blend has no approved therapeutic indication. Effective with the FDA's September 29, 2023 update, both BPC-157 and the TB-500 (LKKTETQ) fragment are 503A Category 2 bulk substances flagged for significant safety risks ^[9]. Both constituents are prohibited by WADA — BPC-157 under S0, and TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories ^[5].